Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application. © 2013 Landes Bioscience.
CITATION STYLE
Mannie, M. D., & Curtis, A. D. (2013, May). Tolerogenic vaccines for multiple sclerosis. Human Vaccines and Immunotherapeutics. https://doi.org/10.4161/hv.23685
Mendeley helps you to discover research relevant for your work.